Literature DB >> 17329110

A conformational transition in the adenylyl cyclase catalytic site yields different binding modes for ribosyl-modified and unmodified nucleotide inhibitors.

Jenna L Wang1, Jian-Xin Guo, Qi-Yuan Zhang, Jay J-Q Wu, Roland Seifert, Gerald H Lushington.   

Abstract

Adenylyl cyclases (ACs) are promising pharmacological targets for treating heart failure, cancer, and psychosis. Ribose-substituted nucleotides have been reported as a potent family of AC inhibitors. In silico analysis of the docked conformers of such nucleotides in AC permits assembly of a consistent, intuitive QSAR model with strong correlation relative to measured pK(i) values. Energy decomposition suggests that the MANT group effects an AC conformational transition upon ligand binding.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17329110      PMCID： PMC2023969          DOI： 10.1016/j.bmc.2007.02.014

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN： 0968-0896            Impact factor:   3.641


  23 in total

1.  Truncation and alanine-scanning mutants of type I adenylyl cyclase.

Authors:  W J Tang; M Stanzel; A G Gilman
Journal:  Biochemistry       Date:  1995-11-07       Impact factor: 3.162

2.  Prediction of drug binding affinities by comparative binding energy analysis.

Authors:  A R Ortiz; M T Pisabarro; F Gago; R C Wade
Journal:  J Med Chem       Date:  1995-07-07       Impact factor: 7.446

Review 3.  Cannabimimetic fatty acid derivatives in cancer and inflammation.

Authors:  V Di Marzo; D Melck; L De Petrocellis; T Bisogno
Journal:  Prostaglandins Other Lipid Mediat       Date:  2000-04       Impact factor: 3.072

4.  Broad specificity of mammalian adenylyl cyclase for interaction with 2',3'-substituted purine- and pyrimidine nucleotide inhibitors.

Authors:  Tung-Chung Mou; Andreas Gille; Srividya Suryanarayana; Mark Richter; Roland Seifert; Stephen R Sprang
Journal:  Mol Pharmacol       Date:  2006-06-09       Impact factor: 4.436

5.  A docking score function for estimating ligand-protein interactions: application to acetylcholinesterase inhibition.

Authors:  Jianxin Guo; Margaret M Hurley; Jeffery B Wright; Gerald H Lushington
Journal:  J Med Chem       Date:  2004-10-21       Impact factor: 7.446

6.  Mice deficient for soluble adenylyl cyclase are infertile because of a severe sperm-motility defect.

Authors:  Gloria Esposito; Bijay S Jaiswal; Fang Xie; Magda A M Krajnc-Franken; Tamara J A A Robben; Ankie M Strik; Cor Kuil; Ria L A Philipsen; Marcel van Duin; Marco Conti; Jan A Gossen; Byjay S Jaiswal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-19       Impact factor: 11.205

7.  Distinct interactions of GTP, UTP, and CTP with G(s) proteins.

Authors:  Andreas Gille; Hui-Yu Liu; Stephen R Sprang; Roland Seifert
Journal:  J Biol Chem       Date:  2002-06-21       Impact factor: 5.157

8.  2'(3')-O-(N-methylanthraniloyl)-substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors.

Authors:  Andreas Gille; Roland Seifert
Journal:  J Biol Chem       Date:  2003-02-03       Impact factor: 5.157

9.  Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload.

Authors:  Satoshi Okumura; Gen Takagi; Jun-ichi Kawabe; Guiping Yang; Ming-Chih Lee; Chull Hong; Jing Liu; Dorothy E Vatner; Junichi Sadoshima; Stephen F Vatner; Yoshihiro Ishikawa
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-06       Impact factor: 11.205

10.  Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides.

Authors:  Andreas Gille; Gerald H Lushington; Tung-Chung Mou; Michael B Doughty; Roger A Johnson; Roland Seifert
Journal:  J Biol Chem       Date:  2004-02-23       Impact factor: 5.157
View more
  6 in total

1.  Inhibition of the adenylyl cyclase toxin, edema factor, from Bacillus anthracis by a series of 18 mono- and bis-(M)ANT-substituted nucleoside 5'-triphosphates.

Authors:  Hesham Taha; Stefan Dove; Jens Geduhn; Burkhard König; Yuequan Shen; Wei-Jen Tang; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-24       Impact factor: 3.000

2.  Structural basis for the high-affinity inhibition of mammalian membranous adenylyl cyclase by 2',3'-o-(N-methylanthraniloyl)-inosine 5'-triphosphate.

Authors:  Melanie Hübner; Anshuman Dixit; Tung-Chung Mou; Gerald H Lushington; Cibele Pinto; Andreas Gille; Jens Geduhn; Burkhard König; Stephen R Sprang; Roland Seifert
Journal:  Mol Pharmacol       Date:  2011-04-15       Impact factor: 4.436

3.  Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2'(3')-O-(N-(methyl)anthraniloyl)-substituted purine and pyrimidine nucleotides.

Authors:  Hesham M Taha; Jennifer Schmidt; Martin Göttle; Srividya Suryanarayana; Yuequan Shen; Wei-Jen Tang; Andreas Gille; Jens Geduhn; Burkhard König; Stefan Dove; Roland Seifert
Journal:  Mol Pharmacol       Date:  2008-12-04       Impact factor: 4.436

4.  Structure-activity relationships for the interactions of 2'- and 3'-(O)-(N-methyl)anthraniloyl-substituted purine and pyrimidine nucleotides with mammalian adenylyl cyclases.

Authors:  Cibele Pinto; Gerald H Lushington; Mark Richter; Andreas Gille; Jens Geduhn; Burkhard König; Tung-Chung Mou; Stephen R Sprang; Roland Seifert
Journal:  Biochem Pharmacol       Date:  2011-05-18       Impact factor: 5.858

5.  Novel inhibitors of anthrax edema factor.

Authors:  Deliang Chen; Milind Misra; Laurie Sower; Johnny W Peterson; Glen E Kellogg; Catherine H Schein
Journal:  Bioorg Med Chem       Date:  2008-06-28       Impact factor: 3.641

Review 6.  Capturing adenylyl cyclases as potential drug targets.

Authors:  Sandra Pierre; Thomas Eschenhagen; Gerd Geisslinger; Klaus Scholich
Journal:  Nat Rev Drug Discov       Date:  2009-04       Impact factor: 84.694
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.